Relay Therapeutics Inc

The confirmed Bearish Pivot Point and price below the 9-, 20-, and 50-day moving averages signal a shift into a medium-term mean-reversion phase (Stage 4), with failed upside control. Short-term price is rejecting the EMA band and the RSI is neutral, indicating execution readiness for bearish engagement now. While the long-term uptrend remains intact above the rising 200-day SMA, downside momentum is likely to persist toward lower support levels. Sell now into rallies up toward the $18.94–$19.37 EMA resistance zone.

• ↑Cash $910.9M ensures operations into 2029, supporting pipeline
• ↑Phase 3 zovegalisib trial initiation expected early 2027
• ↓Q2 revenue fell to $0.4M (-42.9% YoY), showing weak uptake